Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases
Open Access
- 1 November 2002
- journal article
- other
- Published by BMJ in Journal of Clinical Pathology
- Vol. 55 (11), 877-878
- https://doi.org/10.1136/jcp.55.11.877
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Biology of Osteoclast Activation in CancerJournal of Clinical Oncology, 2001
- Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the boneJCI Insight, 2001
- Osteoprotegerin and rank ligand expression in prostate cancerUrology, 2001
- Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Giant Cell Tumor of BoneThe American Journal of Pathology, 2000
- Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic MetastasesCritical Reviews™ in Eukaryotic Gene Expression, 2000
- Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1Endocrinology, 1999
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998